{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:44:22Z","timestamp":1792453462197,"version":"4.5.0"},"reference-count":174,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40263-025-01260-x","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T04:22:46Z","timestamp":1769487766000},"page":"283-303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines"],"prefix":"10.1007","volume":"40","author":[{"given":"Bassem","family":"Yamout","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riadh","family":"Gouider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Al-Roughani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Aljarallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevine","family":"Shalaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaber","family":"Al-Khabouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihad","family":"Inshasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Mahdawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Shatila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6842-5609","authenticated-orcid":false,"given":"Maya","family":"Zeineddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarmad","family":"Al-Mashetah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Canibano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Bohlega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema","family":"Abdulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilham","family":"Slassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aly","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magd","family":"Zakaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"AlJumah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser","family":"Al-Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"1260_CR1","unstructured":"Shumway CL, Patel BC, Tripathy K, De Jesus O. Neuromyelitis optica spectrum disorder (NMOSD). StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2025, StatPearls Publishing LLC.; 2025."},{"issue":"7","key":"1260_CR2","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614\u201325.","journal-title":"N Engl J Med"},{"issue":"7","key":"1260_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1177\/1756285617709723","volume":"10","author":"SM Kim","year":"2017","unstructured":"Kim SM, Kim SJ, Lee HJ, Kuroda H, Palace J, Fujihara K. Differential diagnosis of neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord. 2017;10(7):265\u201389.","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"1260_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177\u201389.","journal-title":"Neurology"},{"key":"1260_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jocn.2022.08.020","volume":"105","author":"F Nabizadeh","year":"2022","unstructured":"Nabizadeh F, Masrouri S, Sharifkazemi H, Azami M, Nikfarjam M, Moghadasi AN. Autologous hematopoietic stem cell transplantation in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. J Clin Neurosci. 2022;105:37\u201344.","journal-title":"J Clin Neurosci"},{"issue":"10","key":"1260_CR6","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","volume":"264","author":"SHM Hamid","year":"2017","unstructured":"Hamid SHM, Whittam D, Mutch K, Linaker S, Solomon T, Das K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017;264(10):2088\u201394.","journal-title":"J Neurol"},{"issue":"3","key":"1260_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD panel proposed criteria. Lancet Neurol. 2023;22(3):268\u201382.","journal-title":"Lancet Neurol"},{"issue":"10","key":"1260_CR8","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1111\/ene.15983","volume":"30","author":"P Zara","year":"2023","unstructured":"Zara P, Dinoto A, Carta S, Floris V, Turilli D, Budhram A, et al. Non-demyelinating disorders mimicking and misdiagnosed as NMOSD: a literature review. Eur J Neurol. 2023;30(10):3367\u201376.","journal-title":"Eur J Neurol"},{"key":"1260_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104459","volume":"69","author":"C Oreja-Guevara","year":"2023","unstructured":"Oreja-Guevara C, Brownlee W, Celius EG, Centonze D, Giovannoni G, Hodgkinson S, et al. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: systematic literature review of real-world evidence. Mult Scler Relat Disord. 2023;69:104459.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"1260_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3988\/jcn.2022.18.2.152","volume":"18","author":"MV Jeyalatha","year":"2022","unstructured":"Jeyalatha MV, Therese KL, Anand AR. An update on the laboratory diagnosis of neuromyelitis optica spectrum disorders. J Clin Neurol. 2022;18(2):152\u201362.","journal-title":"J Clin Neurol"},{"issue":"1","key":"1260_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/13524585241292797","volume":"31","author":"E Carnero Contentti","year":"2025","unstructured":"Carnero Contentti E, Rotstein D, Okuda DT, Paul F. How to avoid missing a diagnosis of neuromyelitis optica spectrum disorder. Mult Scler. 2025;31(1):8\u201322.","journal-title":"Mult Scler"},{"issue":"3","key":"1260_CR12","volume":"13","author":"S Paudel","year":"2021","unstructured":"Paudel S, Nepal G, Guragain S, Shah S, Paudel BS, Ojha R, et al. Longitudinally extensive transverse myelitis: a retrospective study differentiating neuromyelitis optica spectrum disorder from other etiologies. Cureus. 2021;13(3):e13968.","journal-title":"Cureus"},{"issue":"1","key":"1260_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1001\/jamaneurol.2014.2137","volume":"72","author":"EP Flanagan","year":"2015","unstructured":"Flanagan EP, Weinshenker BG, Krecke KN, Lennon VA, Lucchinetti CF, McKeon A, et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol. 2015;72(1):81\u20137.","journal-title":"JAMA Neurol"},{"issue":"17","key":"1260_CR14","doi-asserted-by":"publisher","first-page":"e1642","DOI":"10.1212\/WNL.0000000000006392","volume":"91","author":"E Shosha","year":"2018","unstructured":"Shosha E, Dubey D, Palace J, Nakashima I, Jacob A, Fujihara K, et al. Area postrema syndrome: frequency, criteria, and severity in AQP4-IgG-positive NMOSD. Neurology. 2018;91(17):e1642\u201351.","journal-title":"Neurology"},{"issue":"10","key":"1260_CR15","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","volume":"24","author":"X Montalban","year":"2025","unstructured":"Montalban X, Lebrun-Fr\u00e9nay C, Oh J, Arrambide G, Moccia M, Pia Amato M, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025;24(10):850\u201365.","journal-title":"Lancet Neurol"},{"key":"1260_CR16","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/B978-0-323-95061-9.00033-3","volume-title":"Allergic and immunologic diseases","author":"Y Rodr\u00edguez","year":"2022","unstructured":"Rodr\u00edguez Y, Restrepo L, Chang C, Anaya J-M. Chapter 33 - Neurologic autoimmune diseases. In: Chang C, editor. Allergic and immunologic diseases. Academic Press: Berlin; 2022. p. 887\u2013975."},{"issue":"1","key":"1260_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-38271-x","volume":"13","author":"JM Seok","year":"2023","unstructured":"Seok JM, Cho W, Chung YH, Ju H, Kim ST, Seong J-K, et al. Differentiation between multiple sclerosis and neuromyelitis optica spectrum disorder using a deep learning model. Sci Rep. 2023;13(1):11625.","journal-title":"Sci Rep"},{"key":"1260_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101452","volume":"37","author":"P Wildner","year":"2020","unstructured":"Wildner P, Stasio\u0142ek M, Matysiak M. Differential diagnosis of multiple sclerosis and other inflammatory CNS diseases. Mult Scler Relat Disord. 2020;37:101452.","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"1260_CR19","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","volume":"68","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology. 2007;68(8):603\u20135.","journal-title":"Neurology"},{"issue":"14","key":"1260_CR20","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1177\/1352458519893093","volume":"26","author":"S Salama","year":"2020","unstructured":"Salama S, Khan M, Shanechi A, Levy M, Izbudak I. MRI differences between MOG antibody disease and AQP4 NMOSD. Mult Scler. 2020;26(14):1854\u201365.","journal-title":"Mult Scler"},{"key":"1260_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104611","volume":"72","author":"E Carnero Contentti","year":"2023","unstructured":"Carnero Contentti E, L\u00f3pez PA, Criniti J, Pettinicchi JP, Cristiano E, Patrucco L, et al. Clinical outcomes and prognostic factors in patients with optic neuritis related to NMOSD and MOGAD in distinct ethnic groups from Latin America. Mult Scler Relat Disord. 2023;72:104611.","journal-title":"Mult Scler Relat Disord"},{"key":"1260_CR22","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3389\/fneur.2020.00537","volume":"11","author":"E Khalilidehkordi","year":"2020","unstructured":"Khalilidehkordi E, Clarke L, Arnett S, Bukhari W, Jimenez Sanchez S, O\u2019Gorman C, et al. Relapse patterns in NMOSD: evidence for earlier occurrence of optic neuritis and possible seasonal variation. Front Neurol. 2020;11:537.","journal-title":"Front Neurol"},{"key":"1260_CR23","volume":"2012","author":"W Kim","year":"2012","unstructured":"Kim W, Kim SH, Huh SY, Kim HJ. Brain abnormalities in neuromyelitis optica spectrum disorder. Mult Scler Int. 2012;2012:735486.","journal-title":"Mult Scler Int"},{"issue":"4","key":"1260_CR24","first-page":"726","volume":"40","author":"E Bulut","year":"2019","unstructured":"Bulut E, Karakaya J, Salama S, Levy M, Huisman T, Izbudak I. Brain MRI findings in pediatric-onset neuromyelitis optica spectrum disorder: challenges in differentiation from acute disseminated encephalomyelitis. AJNR Am J Neuroradiol. 2019;40(4):726\u201331.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"2","key":"1260_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ana.24554","volume":"79","author":"I Kleiter","year":"2016","unstructured":"Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, et al. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016;79(2):206\u201316.","journal-title":"Ann Neurol"},{"key":"1260_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00932","volume":"11","author":"T Akaishi","year":"2020","unstructured":"Akaishi T, Takeshita T, Himori N, Takahashi T, Misu T, Ogawa R, et al. Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-positive NMOSD. Front Neurol. 2020;11:932.","journal-title":"Front Neurol"},{"key":"1260_CR27","doi-asserted-by":"crossref","unstructured":"Wang L, Du L, Li Q, Li F, Wang B, Zhao Y, et al. Neuromyelitis optica spectrum disorder with anti-aquaporin-4 antibody: outcome prediction models. Front Immunol. 2022;13.","DOI":"10.3389\/fimmu.2022.873576"},{"issue":"4","key":"1260_CR28","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1177\/1352458508100837","volume":"15","author":"M Bonnan","year":"2009","unstructured":"Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler. 2009;15(4):487\u201392.","journal-title":"Mult Scler"},{"issue":"12","key":"1260_CR29","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1007\/s00415-020-10257-z","volume":"268","author":"S Siritho","year":"2021","unstructured":"Siritho S, Nopsopon T, Pongpirul K. Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis. J Neurol. 2021;268(12):4549\u201362.","journal-title":"J Neurol"},{"issue":"6","key":"1260_CR30","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","volume":"46","author":"BG Weinshenker","year":"1999","unstructured":"Weinshenker BG, O\u2019Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46(6):878\u201386.","journal-title":"Ann Neurol"},{"issue":"1","key":"1260_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/jca.21953","volume":"37","author":"SC Boedecker","year":"2022","unstructured":"Boedecker SC, Luessi F, Engel S, Kraus D, Klimpke P, Holtz S, et al. Immunoadsorption and plasma exchange\u2014efficient treatment options for neurological autoimmune diseases. J Clin Apher. 2022;37(1):70\u201381.","journal-title":"J Clin Apher"},{"issue":"6","key":"1260_CR32","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000504","volume":"5","author":"I Kleiter","year":"2018","unstructured":"Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, et al. Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm. 2018;5(6):e504.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"4","key":"1260_CR33","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000572","volume":"6","author":"H Stiebel-Kalish","year":"2019","unstructured":"Stiebel-Kalish H, Hellmann MA, Mimouni M, Paul F, Bialer O, Bach M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflammation. 2019;6(4):e572.","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"1","key":"1260_CR34","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","volume":"271","author":"T K\u00fcmpfel","year":"2024","unstructured":"K\u00fcmpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, H\u00e4u\u00dfler V, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)\u2014revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. J Neurol. 2024;271(1):141\u201376.","journal-title":"J Neurol"},{"issue":"1","key":"1260_CR35","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12974-022-02420-2","volume":"19","author":"S Demuth","year":"2022","unstructured":"Demuth S, Guillaume M, Bourre B, Ciron J, Zephir H, Sirejacob Y, et al. Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. J Neuroinflammation. 2022;19(1):62.","journal-title":"J Neuroinflammation"},{"issue":"4","key":"1260_CR36","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/1352458513495938","volume":"20","author":"L Elsone","year":"2014","unstructured":"Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler. 2014;20(4):501\u20134.","journal-title":"Mult Scler"},{"issue":"3","key":"1260_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/jca.22129","volume":"39","author":"G Siwach","year":"2024","unstructured":"Siwach G, Hans R, Takkar A, Ahuja CK, Lamba DS, Lal V, et al. Comparison of efficacy of plasma exchange versus intravenous immunoglobulin as an add-on therapy in acute attacks of neuromyelitis optica spectrum disorder. J Clin Apher. 2024;39(3):e22129.","journal-title":"J Clin Apher"},{"issue":"11","key":"1260_CR38","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1177\/1352458514525870","volume":"20","author":"L Elsone","year":"2014","unstructured":"Elsone L, Kitley J, Luppe S, Lythgoe D, Mutch K, Jacob S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler J. 2014;20(11):1533\u201340.","journal-title":"Mult Scler J"},{"issue":"1","key":"1260_CR39","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000005","volume":"1","author":"M Levy","year":"2014","unstructured":"Levy M, Mealy MA. Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2014;1(1):e5.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9","key":"1260_CR40","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1007\/s10072-021-05079-4","volume":"42","author":"J Lin","year":"2021","unstructured":"Lin J, Xue B, Zhu R, Pan J, Li J, Lin Y, et al. Intravenous immunoglobulin as the rescue treatment in NMOSD patients. Neurol Sci. 2021;42(9):3857\u201363.","journal-title":"Neurol Sci"},{"issue":"25","key":"1260_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015944","volume":"98","author":"MA Mealy","year":"2019","unstructured":"Mealy MA, Levy M. A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder. Medicine Baltimore. 2019;98(25):e15944.","journal-title":"Medicine Baltimore"},{"issue":"23","key":"1260_CR42","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1212\/01.wnl.0000303817.82134.da","volume":"70","author":"M Matiello","year":"2008","unstructured":"Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70(23):2197\u2013200.","journal-title":"Neurology"},{"issue":"3","key":"1260_CR43","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/ana.20770","volume":"59","author":"BG Weinshenker","year":"2006","unstructured":"Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006;59(3):566\u20139.","journal-title":"Ann Neurol"},{"key":"1260_CR44","doi-asserted-by":"crossref","unstructured":"Masuda H, Mori M, Uzawa A, Muto M, Uchida T, Ohtani R, et al. Recovery from optic neuritis attack in neuromyelitis optica spectrum disorder and multiple sclerosis. J Neurol Sci. 2016;367.","DOI":"10.1016\/j.jns.2016.06.036"},{"issue":"5","key":"1260_CR45","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209147","volume":"102","author":"V Papp","year":"2024","unstructured":"Papp V, Magyari M, M\u00f6ller S, Sellebjerg F, Battistini JL, Svendsen KB, et al. Mortality of the Danish nationwide AQP4 antibody-seropositive neuromyelitis optica spectrum disorder patient cohort. Neurology. 2024;102(5):e209147.","journal-title":"Neurology"},{"issue":"5","key":"1260_CR46","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1212\/01.WNL.0000049912.02954.2C","volume":"60","author":"DM Wingerchuk","year":"2003","unstructured":"Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology. 2003;60(5):848\u201353.","journal-title":"Neurology"},{"issue":"12","key":"1260_CR47","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1002\/art.42646","volume":"75","author":"MB Humphrey","year":"2023","unstructured":"Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2023;75(12):2088\u2013102.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"1260_CR48","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1177\/1352458507077189","volume":"13","author":"S Watanabe","year":"2007","unstructured":"Watanabe S, Misu T, Miyazawa I, Nakashima I, Shiga Y, Fujihara K, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler. 2007;13(8):968\u201374.","journal-title":"Mult Scler"},{"issue":"5","key":"1260_CR49","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1136\/jnnp-2012-303121","volume":"84","author":"P Cabre","year":"2013","unstructured":"Cabre P, Olindo S, Marignier R, Jeannin S, Merle H, Smadja D. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry. 2013;84(5):511\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"1260_CR50","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/jnnp-2012-304774","volume":"84","author":"J Kitley","year":"2013","unstructured":"Kitley J, Elsone L, George J, Waters P, Woodhall M, Vincent A, et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry. 2013;84(8):918\u201321.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"1260_CR51","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","volume":"264","author":"Z Nikoo","year":"2017","unstructured":"Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017;264(9):2003\u20139.","journal-title":"J Neurol"},{"key":"1260_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103181","volume":"55","author":"Y Wang","year":"2021","unstructured":"Wang Y, Ma J, Chang H, Zhang X, Yin L. Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: an update systematic review and meta -analysis. Mult Scler Relat Disord. 2021;55:103181.","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"1260_CR53","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2169\/internalmedicine.52.7885","volume":"52","author":"H Yaguchi","year":"2013","unstructured":"Yaguchi H, Sakushima K, Takahashi I, Nishimura H, Yashima-Yamada M, Nakamura M, et al. Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Intern Med. 2013;52(9):969\u201372.","journal-title":"Intern Med"},{"issue":"8","key":"1260_CR54","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","volume":"17","author":"J Sellner","year":"2010","unstructured":"Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17(8):1019\u201332.","journal-title":"Eur J Neurol"},{"key":"1260_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102428","volume":"45","author":"E Carnero Contentti","year":"2020","unstructured":"Carnero Contentti E, Rojas JI, Cristiano E, Marques VD, Flores-Rivera J, Lana-Peixoto M, et al. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Mult Scler Relat Disord. 2020;45:102428.","journal-title":"Mult Scler Relat Disord."},{"key":"1260_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104062","volume":"66","author":"E Shosha","year":"2022","unstructured":"Shosha E, Aljarallah SA, Al Fugham N, Al-Jedai AH, Al Luqmani MM, Al Malik YM, et al. Saudi consensus recommendations on the management of neuromyelitis optica spectrum disorders (NMOSD). Multiple Scler Relat Disord. 2022;66:104062.","journal-title":"Multiple Scler Relat Disord"},{"issue":"7","key":"1260_CR57","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","volume":"77","author":"C Costanzi","year":"2011","unstructured":"Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011;77(7):659\u201366.","journal-title":"Neurology"},{"issue":"1","key":"1260_CR58","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","volume":"271","author":"T K\u00fcmpfel","year":"2024","unstructured":"K\u00fcmpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, H\u00e4u\u00dfler V, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. J Neurol. 2024;271(1):141\u201376.","journal-title":"J Neurol"},{"issue":"3","key":"1260_CR59","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","volume":"71","author":"MA Mealy","year":"2014","unstructured":"Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71(3):324\u201330.","journal-title":"JAMA Neurol"},{"key":"1260_CR60","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","volume":"385","author":"Y Yang","year":"2018","unstructured":"Yang Y, Wang CJ, Wang BJ, Zeng ZL, Guo SG. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. J Neurol Sci. 2018;385:192\u20137.","journal-title":"J Neurol Sci"},{"key":"1260_CR61","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.msard.2019.05.011","volume":"33","author":"AI Espiritu","year":"2019","unstructured":"Espiritu AI, Pasco PMD. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Mult Scler Relat Disord. 2019;33:22\u201332.","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"1260_CR62","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","volume":"19","author":"C Zhang","year":"2020","unstructured":"Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19(5):391\u2013401.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1260_CR63","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/ene.13186","volume":"24","author":"H Chen","year":"2017","unstructured":"Chen H, Qiu W, Zhang Q, Wang J, Shi Z, Liu J, et al. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. Eur J Neurol. 2017;24(1):219\u201326.","journal-title":"Eur J Neurol"},{"issue":"4","key":"1260_CR64","first-page":"Cd003982","volume":"2007","author":"I Casetta","year":"2007","unstructured":"Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. Cochrane Database Syst Rev. 2007;2007(4):Cd003982.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"1260_CR65","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2165\/00019053-200624080-00004","volume":"24","author":"VL Priest","year":"2006","unstructured":"Priest VL, Begg EJ, Gardiner SJ, Frampton CM, Gearry RB, Barclay ML, et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics. 2006;24(8):767\u201381.","journal-title":"Pharmacoeconomics"},{"key":"1260_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105452","volume":"83","author":"DL San Martin","year":"2024","unstructured":"San Martin DL, Fukuda TG, Nascimento TS, Silva MB, Filho MBP, Forcadela M, et al. Predictors of azathioprine and mycophenolate mofetil response in patients with neuromyelitis optica spectrum disorder: a cohort study. Mult Scler Relat Disord. 2024;83:105452.","journal-title":"Mult Scler Relat Disord"},{"key":"1260_CR67","doi-asserted-by":"crossref","unstructured":"Songwisit S, Kosiyakul P, Jitprapaikulsan J, Prayoonwiwat N, Ungprasert P, Siritho S. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. Sci Rep. 2020;7 (1):16727.","DOI":"10.1038\/s41598-020-73882-8"},{"key":"1260_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.891064","volume":"13","author":"J Lin","year":"2022","unstructured":"Lin J, Xue B, Li J, Zhu R, Pan J, Chen Z, et al. Comparison of long-term use of low dose rituximab and mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorder. Front Neurol. 2022;13:891064.","journal-title":"Front Neurol"},{"issue":"2","key":"1260_CR69","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1055\/s-0036-1597933","volume":"6","author":"RI Kylat","year":"2017","unstructured":"Kylat RI. What is the teratogenic risk of mycophenolate? J Pediatr Genet. 2017;6(2):111\u20134.","journal-title":"J Pediatr Genet."},{"issue":"2","key":"1260_CR70","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/cen3.12189","volume":"6","author":"ASL Ng","year":"2015","unstructured":"Ng ASL, Tan K. Methotrexate is effective for the treatment of neuromyelitis optica spectrum disorders in Asian patients. Clinical and Experimental Neuroimmunology. 2015;6(2):149\u201353.","journal-title":"Clinical and Experimental Neuroimmunology."},{"key":"1260_CR71","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1471-2377-14-51","volume":"14","author":"RS Ramanathan","year":"2014","unstructured":"Ramanathan RS, Malhotra K, Scott T. Treatment of neuromyelitis optica\/neuromyelitis optica spectrum disorders with methotrexate. BMC Neurol. 2014;14:51.","journal-title":"BMC Neurol"},{"issue":"9","key":"1260_CR72","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","volume":"70","author":"S-H Kim","year":"2013","unstructured":"Kim S-H, Huh S-Y, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70(9):1110\u20137.","journal-title":"JAMA Neurol"},{"issue":"9","key":"1260_CR73","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","volume":"72","author":"SH Kim","year":"2015","unstructured":"Kim SH, Jeong IH, Hyun JW, Joung A, Jo HJ, Hwang SH, et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol. 2015;72(9):989\u201395.","journal-title":"JAMA Neurol"},{"issue":"4","key":"1260_CR74","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","volume":"19","author":"M Tahara","year":"2020","unstructured":"Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(4):298\u2013306.","journal-title":"Lancet Neurol"},{"key":"1260_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.626323","volume":"9","author":"X Gao","year":"2021","unstructured":"Gao X, Wang Y, Xu Z, Deng H, Yang H, Zhong F. Systematic review and meta-analysis of rituximab for steroid-dependent or frequently relapsing nephrotic syndrome in children. Front Pediatr. 2021;9:626323.","journal-title":"Front Pediatr"},{"issue":"6","key":"1260_CR76","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, D\u00f6rner T, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"22","key":"1260_CR77","doi-asserted-by":"publisher","first-page":"e2504","DOI":"10.1212\/WNL.0000000000201260","volume":"99","author":"P Barreras","year":"2022","unstructured":"Barreras P, Vasileiou ES, Filippatou AG, Fitzgerald KC, Levy M, Pardo CA, et al. Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease. Neurology. 2022;99(22):e2504\u201316.","journal-title":"Neurology"},{"key":"1260_CR78","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001179","author":"SH Kim","year":"2022","unstructured":"Kim SH, Park NY, Kim KH, Hyun JW, Kim HJ. Rituximab-induced hypogammaglobulinemia and risk of infection in neuromyelitis optica spectrum disorders: a 14-year real-life experience. Neurol Neuroimmunol Neuroinflamm. 2022. https:\/\/doi.org\/10.1212\/NXI.0000000000001179.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1260_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104563","volume":"71","author":"C Rual","year":"2023","unstructured":"Rual C, Biotti D, Lepine Z, Delourme A, Berre JL, Treiner E, et al. 2 grams versus 1 gram rituximab as maintenance schedule in multiple sclerosis, neuromyelitis optica spectrum disorders and related diseases: What B-cell repopulation data tell us. Mult Scler Relat Disord. 2023;71:104563.","journal-title":"Mult Scler Relat Disord."},{"key":"1260_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105528","volume":"85","author":"M Nasir","year":"2024","unstructured":"Nasir M, Hone L, Tallantyre E, Kelly P, Leite MI, Robertson N, et al. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2024;85:105528.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"1260_CR81","volume":"10","author":"MTG Hayes","year":"2024","unstructured":"Hayes MTG, Adam RJ, McCombe PA, Walsh M, Blum S. Long-term efficacy and safety of rituximab in the treatment of neuromyelitis optica spectrum disorder. Mult Scler J. 2024;10(2):20552173241257876.","journal-title":"Mult Scler J"},{"key":"1260_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2024.578285","volume":"387","author":"C Zhang","year":"2024","unstructured":"Zhang C, Liu R, Gao B, Li T, Wang H, Song T, et al. Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder. J Neuroimmunol. 2024;387:578285.","journal-title":"J Neuroimmunol"},{"key":"1260_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1148632","volume":"14","author":"D Zhao","year":"2023","unstructured":"Zhao D, Ren K, Lu J, Liu Z, Li Z, Wu J, et al. Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study. Front Immunol. 2023;14:1148632.","journal-title":"Front Immunol"},{"issue":"4","key":"1260_CR84","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s40120-023-00481-w","volume":"12","author":"N Bruschi","year":"2023","unstructured":"Bruschi N, Malentacchi M, Malucchi S, Sperli F, Martire S, Sala A, et al. Tailoring rituximab according to CD27-positive B-cell versus CD19-positive B-cell monitoring in neuromyelitis optica spectrum disorder and MOG-associated disease: results from a single-center study. Neurol Ther. 2023;12(4):1375\u201383.","journal-title":"Neurol Ther."},{"issue":"1","key":"1260_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1021-2","volume":"18","author":"E Schiopu","year":"2016","unstructured":"Schiopu E, Chatterjee S, Hsu V, Flor A, Cimbora D, Patra K, et al. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther. 2016;18(1):131.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"1260_CR86","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s40265-020-01370-4","volume":"80","author":"JE Frampton","year":"2020","unstructured":"Frampton JE. Inebilizumab: first approval. Drugs. 2020;80(12):1259\u201364.","journal-title":"Drugs"},{"key":"1260_CR87","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200124","author":"F Paul","year":"2023","unstructured":"Paul F, Marignier R, Palace J, Arrambide G, Asgari N, Bennett JL, et al. International delphi consensus on the management of AQP4-IgG+ NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab. Neurol Neuroimmunol Neuroinflamm. 2023. https:\/\/doi.org\/10.1212\/NXI.0000000000200124.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10206","key":"1260_CR88","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet. 2019;394(10206):1352\u201363.","journal-title":"Lancet"},{"key":"1260_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103352","volume":"57","author":"EP Flanagan","year":"2022","unstructured":"Flanagan EP, Levy M, Katz E, Cimbora D, Drappa J, Mealy MA, et al. Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum study. Mult Scler Relat Disord. 2022;57:103352.","journal-title":"Mult Scler Relat Disord"},{"key":"1260_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103356","volume":"57","author":"R Marignier","year":"2022","unstructured":"Marignier R, Pittock SJ, Paul F, Kim HJ, Bennett JL, Weinshenker BG, et al. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2022;57:103356.","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"1260_CR91","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/13524585211047223","volume":"28","author":"M Rensel","year":"2022","unstructured":"Rensel M, Zabeti A, Mealy MA, Cimbora D, She D, Drappa J, et al. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for \u22654\u2009years in the N-MOmentum trial. Mult Scler. 2022;28(6):925\u201332.","journal-title":"Mult Scler"},{"key":"1260_CR92","unstructured":"FDA. Inebilizumab (UPLIZNA) Prescribing Information2020 04 Marc 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761142s000lbl.pdf."},{"issue":"12","key":"1260_CR93","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, Young NS, Schubert J, Brodsky RA, Soci\u00e9 G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233\u201343.","journal-title":"N Engl J Med"},{"issue":"4","key":"1260_CR94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195909","volume":"13","author":"D Sheridan","year":"2018","unstructured":"Sheridan D, Yu ZX, Zhang Y, Patel R, Sun F, Lasaro MA, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS ONE. 2018;13(4):e0195909.","journal-title":"PLoS ONE"},{"issue":"6","key":"1260_CR95","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ana.26626","volume":"93","author":"SJ Pittock","year":"2023","unstructured":"Pittock SJ, Barnett M, Bennett JL, Berthele A, de S\u00e8ze J, Levy M, et al. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol. 2023;93(6):1053\u201368.","journal-title":"Ann Neurol"},{"issue":"17_supplement_2","key":"1260_CR96","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1212\/WNL.0000000000202922","volume":"100","author":"S Pittock","year":"2023","unstructured":"Pittock S, Barnett M, Bennett J, Berthele A, de S\u00e8ze J, Levy M, et al. Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the phase 3 CHAMPION-NMOSD trial (S5.002). Neurology. 2023;100(17_supplement_2):2965.","journal-title":"Neurology"},{"issue":"3","key":"1260_CR97","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40120-024-00597-7","volume":"13","author":"SL Clardy","year":"2024","unstructured":"Clardy SL, Pittock SJ, Aktas O, Nakahara J, Isobe N, Centonze D, et al. Network meta-analysis of ravulizumab and alternative interventions for the treatment of neuromyelitis optica spectrum disorder. Neurol Ther. 2024;13(3):535\u201349.","journal-title":"Neurol Ther"},{"issue":"6","key":"1260_CR98","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","volume":"133","author":"JW Lee","year":"2019","unstructured":"Lee JW, de Sicre Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, F\u00fcreder W, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530\u20139.","journal-title":"Blood"},{"key":"1260_CR99","unstructured":"CDC. Clinical guidance for managing meningococcal disease risk in patients receiving complement inhibitor therapy2024 18 Mar 2025. Available from: https:\/\/www.cdc.gov\/meningococcal\/hcp\/clinical-guidance\/complement-inhibitor.html."},{"issue":"3","key":"1260_CR100","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1017\/S1092852920001625","volume":"26","author":"SJ Pittock","year":"2021","unstructured":"Pittock SJ, Weitz I, Howard JF, Sabatella G, Mehta S, Franklin J. Response to: Eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder. CNS Spectr. 2021;26(3):195\u20136.","journal-title":"CNS Spectr"},{"issue":"9","key":"1260_CR101","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1073\/pnas.1017385108","volume":"108","author":"N Chihara","year":"2011","unstructured":"Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A. 2011;108(9):3701\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1260_CR102","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000311","volume":"4","author":"Y Takeshita","year":"2017","unstructured":"Takeshita Y, Obermeier B, Cotleur AC, Spampinato SF, Shimizu F, Yamamoto E, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2017;4(1):e311.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"1260_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101920","volume":"39","author":"I Lotan","year":"2020","unstructured":"Lotan I, Charlson RW, Ryerson LZ, Levy M, Kister I. Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2020;39:101920.","journal-title":"Mult Scler Relat Disord"},{"issue":"14","key":"1260_CR104","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s40265-020-01380-2","volume":"80","author":"YA Heo","year":"2020","unstructured":"Heo YA. Satralizumab: first approval. Drugs. 2020;80(14):1477\u201382.","journal-title":"Drugs"},{"issue":"22","key":"1260_CR105","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114\u201324.","journal-title":"N Engl J Med"},{"issue":"5","key":"1260_CR106","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402\u201312.","journal-title":"Lancet Neurol"},{"key":"1260_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105502","volume":"84","author":"I Nakashima","year":"2024","unstructured":"Nakashima I, Nakahara J, Yasunaga H, Yamashita M, Nishijima N, Satomura A, et al. Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database. Mult Scler Relat Disord. 2024;84:105502.","journal-title":"Mult Scler Relat Disord."},{"key":"1260_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104025","volume":"66","author":"T Yamamura","year":"2022","unstructured":"Yamamura T, Weinshenker B, Yeaman MR, De Seze J, Patti F, Lobo P, et al. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord. 2022;66:104025.","journal-title":"Mult Scler Relat Disord."},{"key":"1260_CR109","doi-asserted-by":"crossref","unstructured":"Kleiter I, Traboulsee A, Palace J, Yamamura T, Fujihara K, Saiz A, et al. Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. 2023;10(1).","DOI":"10.1212\/NXI.0000000000200071"},{"issue":"2","key":"1260_CR110","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/1352458514541978","volume":"21","author":"R Greco","year":"2015","unstructured":"Greco R, Bondanza A, Oliveira MC, Badoglio M, Burman J, Piehl F, et al. Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party. Mult Scler. 2015;21(2):189\u201397.","journal-title":"Mult Scler"},{"issue":"18","key":"1260_CR111","doi-asserted-by":"publisher","first-page":"e1732","DOI":"10.1212\/WNL.0000000000008394","volume":"93","author":"RK Burt","year":"2019","unstructured":"Burt RK, Balabanov R, Han X, Burns C, Gastala J, Jovanovic B, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. Neurology. 2019;93(18):e1732\u201341.","journal-title":"Neurology"},{"issue":"1","key":"1260_CR112","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","volume":"8","author":"C Qin","year":"2023","unstructured":"Qin C, Tian DS, Zhou LQ, Shang K, Huang L, Dong MH, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Ther. 2023;8(1):5.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"1260_CR113","doi-asserted-by":"publisher","first-page":"e438","DOI":"10.1212\/WNL.0000000000207443","volume":"101","author":"S Demuth","year":"2023","unstructured":"Demuth S, Collongues N, Audoin B, Ayrignac X, Bourre B, Ciron J, et al. Rituximab de-escalation in patients with neuromyelitis optica spectrum disorder. Neurology. 2023;101(4):e438\u201350.","journal-title":"Neurology"},{"key":"1260_CR114","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000947","author":"SH Kim","year":"2021","unstructured":"Kim SH, Jang H, Park NY, Kim Y, Kim SY, Lee MY, et al. Discontinuation of immunosuppressive therapy in patients with neuromyelitis optica spectrum disorder with aquaporin-4 antibodies. Neurol Neuroimmunol Neuroinflamm. 2021. https:\/\/doi.org\/10.1212\/NXI.0000000000000947.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9","key":"1260_CR115","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1177\/1352458519829694","volume":"25","author":"E Shosha","year":"2019","unstructured":"Shosha E. Disease-modifying therapies should be stopped in NMOSD patients in remission - yes. Mult Scler. 2019;25(9):1217\u20138.","journal-title":"Mult Scler"},{"issue":"4","key":"1260_CR116","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000351","volume":"4","author":"L Pandit","year":"2017","unstructured":"Pandit L, Mustafa S. Spontaneous remission lasting more than a decade in untreated AQP4 antibody-positive NMOSD. Neurol Neuroimmunol Neuroinflamm. 2017;4(4):e351.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"1260_CR117","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1177\/0883073814553974","volume":"30","author":"K Weinfurtner","year":"2015","unstructured":"Weinfurtner K, Graves J, Ness J, Krupp L, Milazzo M, Waubant E. Prolonged remission in neuromyelitis optica following cessation of rituximab treatment. J Child Neurol. 2015;30(10):1366\u201370.","journal-title":"J Child Neurol"},{"issue":"11-12","key":"1260_CR118","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1177\/13524585231199819","volume":"29","author":"Y Wu","year":"2023","unstructured":"Wu Y, Geraldes R, Jury\u0144czyk M, Palace J. Double-negative neuromyelitis optica spectrum disorder. Mult Scler. 2023;29(11\u201312):1353\u201362.","journal-title":"Mult Scler"},{"issue":"13","key":"1260_CR119","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1177\/1352458517730131","volume":"24","author":"MA Mealy","year":"2018","unstructured":"Mealy MA, Kim SH, Schmidt F, L\u00f3pez R, Jimenez Arango JA, Paul F, et al. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. Mult Scler. 2018;24(13):1737\u201342.","journal-title":"Mult Scler"},{"issue":"1","key":"1260_CR120","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40120-021-00298-5","volume":"11","author":"Y Yang","year":"2022","unstructured":"Yang Y, Chen L, Wu L, Yao J, Wang N, Su X, et al. Effective rituximab treatment in patients with neuromyelitis optica spectrum disorders compared with azathioprine and mycophenolate. Neurol Ther. 2022;11(1):137\u201349.","journal-title":"Neurol Ther."},{"issue":"7","key":"1260_CR121","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","volume":"72","author":"M Ringelstein","year":"2015","unstructured":"Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, St\u00f6gbauer F, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72(7):756\u201363.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1260_CR122","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1177\/13524585231221664","volume":"30","author":"C Rocchi","year":"2024","unstructured":"Rocchi C, Forcadela M, Kelly P, Linaker S, Gibbons E, Bhojak M, et al. The absence of antibodies in longitudinally extensive transverse myelitis may predict a more favourable prognosis. Mult Scler. 2024;30(3):345\u201356.","journal-title":"Mult Scler"},{"issue":"8","key":"1260_CR123","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1001\/archneurol.2012.249","volume":"69","author":"AM Quek","year":"2012","unstructured":"Quek AM, McKeon A, Lennon VA, Mandrekar JN, Iorio R, Jiao Y, et al. Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol. 2012;69(8):1039\u201343.","journal-title":"Arch Neurol"},{"issue":"9","key":"1260_CR124","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1212\/WNL.0000000000201625","volume":"100","author":"R Pizzolato Umeton","year":"2023","unstructured":"Pizzolato Umeton R, Waltz M, Aaen GS, Benson L, Gorman M, Goyal M, et al. Therapeutic response in pediatric neuromyelitis optica spectrum disorder. Neurology. 2023;100(9):e985\u201394.","journal-title":"Neurology"},{"issue":"4","key":"1260_CR125","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000046","volume":"1","author":"G Longoni","year":"2014","unstructured":"Longoni G, Banwell B, Filippi M, Yeh EA. Rituximab as a first-line preventive treatment in pediatric NMOSDs: preliminary results in 5 children. Neurol Neuroimmunol Neuroinflamm. 2014;1(4):e46.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"1260_CR126","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000188","volume":"3","author":"M Nosadini","year":"2016","unstructured":"Nosadini M, Alper G, Riney CJ, Benson LA, Mohammad SS, Ramanathan S, et al. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflammation. 2016;3(1):e188.","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"2","key":"1260_CR127","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","volume":"83","author":"RC Dale","year":"2014","unstructured":"Dale RC, Brilot F, Duffy LV, Twilt M, Waldman AT, Narula S, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83(2):142\u201350.","journal-title":"Neurology"},{"key":"1260_CR128","first-page":"193","volume":"50","author":"MGS Breu","year":"2919","unstructured":"Breu MGS, Hoftberger R, Freilinger M, Kircher K, Kasprian G, Seidl R, et al. Two cases of pediatric AQP4-antibody positive neuromyelitis optica spectrum disorder successfully treated with tocilizumab. Neuropediatrics. 2919;50:193\u20136.","journal-title":"Neuropediatrics"},{"issue":"2","key":"1260_CR129","first-page":"152","volume":"30","author":"A Perera","year":"2025","unstructured":"Perera A, Chugh N, Garcia-Bournissen F. Systematic review of adverse events of IL-1 and IL-6 inhibitor use in pediatrics. J Pediatr Pharmacol Ther. 2025;30(2):152\u201369.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"1260_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.nerep.2024.100213","volume":"5","author":"M Enriquez","year":"2024","unstructured":"Enriquez M, Rosenthal S, McLendon LA, Bennett JL, Piquet AL, Kammeyer R. Efficacy of eculizumab in acute refractory pediatric neuromyelitis optica: a case report. Neuroimmunol Rep. 2024;5:100213.","journal-title":"Neuroimmunol Rep"},{"issue":"3","key":"1260_CR131","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89(3):701\u201311.","journal-title":"Kidney Int"},{"issue":"4","key":"1260_CR132","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00467-020-04774-2","volume":"36","author":"K Tanaka","year":"2021","unstructured":"Tanaka K, Adams B, Aris AM, Fujita N, Ogawa M, Ortiz S, et al. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Pediatr Nephrol. 2021;36(4):889\u201398.","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"1260_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.bdcasr.2024.100012","volume":"2","author":"M Yonekawa","year":"2024","unstructured":"Yonekawa M, Nishioka M, Yazawa S, Yabe M, Murase T, Matsuoka D, et al. Delayed visual improvement in a pediatric patient with anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder after acute immunomodulatory treatment: a case report. Brain Dev Case Rep. 2024;2(2):100012.","journal-title":"Brain Dev Case Rep"},{"key":"1260_CR134","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000837","author":"RB Paolilo","year":"2020","unstructured":"Paolilo RB, Hacohen Y, Yazbeck E, Armangue T, Bruijstens A, Lechner C, et al. Treatment and outcome of aquaporin-4 antibody-positive NMOSD: a multinational pediatric study. Neurol Neuroimmunol Neuroinflamm. 2020. https:\/\/doi.org\/10.1212\/NXI.0000000000000837.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1260_CR135","doi-asserted-by":"publisher","first-page":"1113406","DOI":"10.3389\/fimmu.2022.1113406","volume":"13","author":"Z Li","year":"2022","unstructured":"Li Z, Wan L, Liu X, Wang J, Shi X, Zhou H, et al. Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis optica spectrum disorder. Front Immunol. 2022;13:1113406.","journal-title":"Front Immunol"},{"issue":"5","key":"1260_CR136","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/ana.24617","volume":"79","author":"EP Flanagan","year":"2016","unstructured":"Flanagan EP, Cabre P, Weinshenker BG, Sauver JS, Jacobson DJ, Majed M, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol. 2016;79(5):775\u201383.","journal-title":"Ann Neurol"},{"key":"1260_CR137","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.msard.2018.08.015","volume":"25","author":"G Delgado-Garc\u00eda","year":"2018","unstructured":"Delgado-Garc\u00eda G, Ch\u00e1vez Z, Rivas-Alonso V, Corona T, Flores-Rivera J. Obstetric outcomes in a Mexican cohort of patients with AQP4-antibody-seropositive neuromyelitis optica. Mult Scler Relat Disord. 2018;25:268\u201370.","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"1260_CR138","volume":"10","author":"AH Gad","year":"2024","unstructured":"Gad AH, Kishk N, Shalaby NM, Heikal ES, Fouad AM, Merghany N, et al. Pregnancy characteristics in Egyptian female patients with NMOSD. Mult Scler J. 2024;10(3):20552173241271878.","journal-title":"Mult Scler J"},{"issue":"16","key":"1260_CR139","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1212\/WNL.0b013e318250d812","volume":"78","author":"W Kim","year":"2012","unstructured":"Kim W, Kim SH, Nakashima I, Takai Y, Fujihara K, Leite MI, et al. Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology. 2012;78(16):1264\u20137.","journal-title":"Neurology"},{"issue":"1","key":"1260_CR140","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1212\/WNL.0000000000002208","volume":"86","author":"MM Nour","year":"2016","unstructured":"Nour MM, Nakashima I, Coutinho E, Woodhall M, Sousa F, Revis J, et al. Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder. Neurology. 2016;86(1):79\u201387.","journal-title":"Neurology"},{"issue":"6","key":"1260_CR141","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.4049\/jimmunol.1301483","volume":"191","author":"S Saadoun","year":"2013","unstructured":"Saadoun S, Waters P, Leite MI, Bennett JL, Vincent A, Papadopoulos MC. Neuromyelitis optica IgG causes placental inflammation and fetal death. J Immunol. 2013;191(6):2999\u20133005.","journal-title":"J Immunol"},{"issue":"2","key":"1260_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103499","volume":"23","author":"P Siriratnam","year":"2024","unstructured":"Siriratnam P, Huda S, Butzkueven H, van der Walt A, Jokubaitis V, Monif M. Risks and outcomes of pregnancy in neuromyelitis optica spectrum disorder: a comprehensive review. Autoimmun Rev. 2024;23(2):103499.","journal-title":"Autoimmun Rev"},{"issue":"14","key":"1260_CR143","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1177\/1352458517740215","volume":"23","author":"E Shosha","year":"2017","unstructured":"Shosha E, Pittock SJ, Flanagan E, Weinshenker BG. Neuromyelitis optica spectrum disorders and pregnancy: interactions and management. Mult Scler. 2017;23(14):1808\u201317.","journal-title":"Mult Scler"},{"issue":"12","key":"1260_CR144","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/acn3.51683","volume":"9","author":"Q Du","year":"2022","unstructured":"Du Q, Shi Z, Chen H, Zhang Y, Qiu Y, Lang Y, et al. Effects of pregnancy on neuromyelitis optica spectrum disorder and predictors of related attacks. Ann Clin Transl Neurol. 2022;9(12):1918\u201325.","journal-title":"Ann Clin Transl Neurol"},{"issue":"11","key":"1260_CR145","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1177\/1352458513498125","volume":"19","author":"M Ringelstein","year":"2013","unstructured":"Ringelstein M, Harmel J, Distelmaier F, Ingwersen J, Menge T, Hellwig K, et al. Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum. Mult Scler. 2013;19(11):1544\u20137.","journal-title":"Mult Scler"},{"issue":"10","key":"1260_CR146","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1007\/s00415-013-7031-y","volume":"260","author":"YD Fragoso","year":"2013","unstructured":"Fragoso YD, Adoni T, Bichuetti DB, Brooks JB, Ferreira ML, Oliveira EM, et al. Neuromyelitis optica and pregnancy. J Neurol. 2013;260(10):2614\u20139.","journal-title":"J Neurol"},{"issue":"22","key":"1260_CR147","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1212\/WNL.0000000000004681","volume":"89","author":"EC Klawiter","year":"2017","unstructured":"Klawiter EC, Bove R, Elsone L, Alvarez E, Borisow N, Cortez M, et al. High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology. 2017;89(22):2238\u201344.","journal-title":"Neurology"},{"issue":"11","key":"1260_CR148","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1177\/1352458515583376","volume":"22","author":"Y Shimizu","year":"2016","unstructured":"Shimizu Y, Fujihara K, Ohashi T, Nakashima I, Yokoyama K, Ikeguch R, et al. Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder. Mult Scler. 2016;22(11):1413\u201320.","journal-title":"Mult Scler"},{"key":"1260_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.nerep.2022.100134","volume":"2","author":"V Tallavajhala","year":"2022","unstructured":"Tallavajhala V, Padarti A, Kilgo W. Neuromyelitis optica spectrum disorder relapse during the third trimester of pregnancy. Neuroimmunol Rep. 2022;2:100134.","journal-title":"Neuroimmunol Rep"},{"issue":"1","key":"1260_CR150","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/13524585221130934","volume":"29","author":"S Vukusic","year":"2023","unstructured":"Vukusic S, Marignier R, Ciron J, Bourre B, Cohen M, Deschamps R, et al. Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society. Mult Scler. 2023;29(1):37\u201351.","journal-title":"Mult Scler"},{"issue":"4","key":"1260_CR151","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-021-00666-4","volume":"23","author":"KM Krysko","year":"2021","unstructured":"Krysko KM, Bove R, Dobson R, Jokubaitis V, Hellwig K. Treatment of women with multiple sclerosis planning pregnancy. Curr Treat Options Neurol. 2021;23(4):11.","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"1260_CR152","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/ibd.22948","volume":"19","author":"M Akbari","year":"2013","unstructured":"Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(1):15\u201322.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"1260_CR153","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","volume":"75","author":"C G\u00f6testam Skorpen","year":"2016","unstructured":"G\u00f6testam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795\u2013810.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1260_CR154","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/ajmg.a.32685","volume":"149a","author":"MT Anderka","year":"2009","unstructured":"Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A. 2009;149a(6):1241\u20138.","journal-title":"Am J Med Genet A"},{"issue":"3","key":"1260_CR155","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ajmg.a.35223","volume":"158a","author":"M Hoeltzenbein","year":"2012","unstructured":"Hoeltzenbein M, Elefant E, Vial T, Finkel-Pekarsky V, Stephens S, Clementi M, et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A. 2012;158a(3):588\u201396.","journal-title":"Am J Med Genet A"},{"issue":"8","key":"1260_CR156","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/S1701-2163(16)34622-9","volume":"32","author":"C Klieger-Grossmann","year":"2010","unstructured":"Klieger-Grossmann C, Chitayat D, Lavign S, Kao K, Garcia-Bournissen F, Quinn D, et al. Prenatal exposure to mycophenolate mofetil: an updated estimate. J Obstet Gynaecol Can. 2010;32(8):794\u20137.","journal-title":"J Obstet Gynaecol Can"},{"key":"1260_CR157","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.reprotox.2019.05.066","volume":"87","author":"EA Verberne","year":"2019","unstructured":"Verberne EA, de Haan E, van Tintelen JP, Lindhout D, van Haelst MM. Fetal methotrexate syndrome: a systematic review of case reports. Reprod Toxicol. 2019;87:125\u201339.","journal-title":"Reprod Toxicol"},{"issue":"3","key":"1260_CR158","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3109\/10408444.2011.653487","volume":"42","author":"JM DeSesso","year":"2012","unstructured":"DeSesso JM, Williams AL, Ahuja A, Bowman CJ, Hurtt ME. The placenta, transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy. Crit Rev Toxicol. 2012;42(3):185\u2013210.","journal-title":"Crit Rev Toxicol"},{"issue":"2","key":"1260_CR159","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1530\/ror.0.0040081","volume":"4","author":"F Saji","year":"1999","unstructured":"Saji F, Samejima Y, Kamiura S, Koyama M. Dynamics of immunoglobulins at the feto-maternal interface. Rev Reprod. 1999;4(2):81\u20139.","journal-title":"Rev Reprod"},{"issue":"3","key":"1260_CR160","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1212\/CON.0000000000000745","volume":"25","author":"AM Langer-Gould","year":"2019","unstructured":"Langer-Gould AM. Pregnancy and family planning in multiple sclerosis. Continuum (Minneap Minn). 2019;25(3):773\u201392.","journal-title":"Continuum (Minneap Minn)"},{"issue":"3","key":"1260_CR161","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000453","volume":"5","author":"G Das","year":"2018","unstructured":"Das G, Damotte V, Gelfand JM, Bevan C, Cree BAC, Do L, et al. Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm. 2018;5(3):e453.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"1260_CR162","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000913","author":"T K\u00fcmpfel","year":"2021","unstructured":"K\u00fcmpfel T, Thiel S, Meinl I, Ciplea AI, Bayas A, Hoffmann F, et al. Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: a cohort study from Germany. Neurol Neuroimmunol Neuroinflamm. 2021. https:\/\/doi.org\/10.1212\/NXI.0000000000000913.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"1260_CR163","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","volume":"117","author":"EF Chakravarty","year":"2011","unstructured":"Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499\u2013506.","journal-title":"Blood"},{"key":"1260_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104760","volume":"75","author":"MI Leite","year":"2023","unstructured":"Leite MI, Panahloo Z, Harrison N, Palace J. A systematic literature review to examine the considerations around pregnancy in women of child-bearing age with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) or aquaporin 4 neuromyelitis optica spectrum disorder (AQP4+ NMOSD). Mult Scler Relat Disord. 2023;75:104760.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"1260_CR165","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40262-021-01092-0","volume":"61","author":"E Leung","year":"2022","unstructured":"Leung E, Crass RL, Jorgensen SCJ, Raybardhan S, Langford BJ, Moore WJ, et al. Pharmacokinetic\/pharmacodynamic considerations of alternate dosing strategies of tocilizumab in COVID-19. Clin Pharmacokinet. 2022;61(2):155\u201365.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"1260_CR166","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","volume":"373","author":"RJ Kelly","year":"2015","unstructured":"Kelly RJ, H\u00f6chsmann B, Szer J, Kulasekararaj A, Guibert Sd, R\u00f6th A, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373(11):1032\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"1260_CR167","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/bcpt.12367","volume":"116","author":"AM Bj\u00f8rn","year":"2015","unstructured":"Bj\u00f8rn AM, Ehrenstein V, Nohr EA, N\u00f8rgaard M. Use of inhaled and oral corticosteroids in pregnancy and the risk of malformations or miscarriage. Basic Clin Pharmacol Toxicol. 2015;116(4):308\u201314.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"1260_CR168","doi-asserted-by":"publisher","first-page":"585.e1","DOI":"10.1016\/j.ajog.2007.05.046","volume":"197","author":"SL Carmichael","year":"2007","unstructured":"Carmichael SL, Shaw GM, Ma C, Werler MM, Rasmussen SA, Lammer EJ. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol. 2007;197(6):585.e1-7 (discussion 683-4, e1-7).","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"1260_CR169","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1503\/cmaj.101063","volume":"183","author":"A Hviid","year":"2011","unstructured":"Hviid A, M\u00f8lgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011;183(7):796\u2013804.","journal-title":"CMAJ"},{"issue":"6","key":"1260_CR170","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-Z","volume":"62","author":"L Park-Wyllie","year":"2000","unstructured":"Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385\u201392.","journal-title":"Teratology"},{"issue":"9","key":"1260_CR171","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.annepidem.2014.06.005","volume":"24","author":"H Skuladottir","year":"2014","unstructured":"Skuladottir H, Wilcox A, McConnaughey R, Vindenes H, Lie RT. First-trimester nonsystemic corticosteroid use and the risk of oral clefts in Norway. Ann Epidemiol. 2014;24(9):635\u201340.","journal-title":"Ann Epidemiol"},{"issue":"1","key":"1260_CR172","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/21556660.2020.1721507","volume":"9","author":"B Caniba\u00f1o","year":"2020","unstructured":"Caniba\u00f1o B, Deleu D, Mesraoua B, Melikyan G, Ibrahim F, Hanssens Y. Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations. J Drug Assess. 2020;9(1):20\u201336.","journal-title":"J Drug Assess"},{"issue":"3","key":"1260_CR173","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41582-020-0313-y","volume":"16","author":"Y Mao-Draayer","year":"2020","unstructured":"Mao-Draayer Y, Thiel S, Mills EA, Chitnis T, Fabian M, Katz Sand I, et al. Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations. Nat Rev Neurol. 2020;16(3):154\u201370.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"1260_CR174","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bjh.15790","volume":"185","author":"G Soci\u00e9","year":"2019","unstructured":"Soci\u00e9 G, Caby-Tosi MP, Marantz JL, Cole A, Bedrosian CL, Gasteyger C, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol. 2019;185(2):297\u2013310.","journal-title":"Br J Haematol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01260-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01260-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01260-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:03:38Z","timestamp":1771430618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01260-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":174,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1260"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01260-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript represents the views and opinions of the members involved in the development of the guidelines. All authors declare that they have no conflicts of interest related to the content of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All authors participated as members of the panel of experts in the meetings that led to the development of the manuscript. All authors actively contributed to the discussion and the consensus reached and drafted part of the manuscript. Bassem Yamout and Maya Zeineddine drafted the initial version of the manuscript and all authors discussed and reviewed the final version of the manuscript. All authors read and approved the final submitted manuscript and agree to be accountable for the work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}